Apellis Pharmaceuticals, Inc.
APLSDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001492422
Apellis Pharmaceuticals, Inc. was delisted in 2026; its insiders filed their last Form 4 on May 14, 2026; 324 institutions reported holding it in 13F filings for Q1 2026, worth $5.56B in total; Soros Fund Management was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Apellis Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Apellis Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Wheeler Craig A | Director | 0 | May 14, 2026 | 2 |
| Dolsten Mikael | Director | 0 | May 14, 2026 | 2 |
| Machiels Alec | Director | 0 | May 14, 2026 | 2 |
| Chan Gerald | Director | 0 | May 14, 2026 | 2 |
| Watson David O. | General Counsel | 0 | May 14, 2026 | 9 |
| Deschatelets Pascal | Chief Scientific Officer | 0 | May 14, 2026 | 5 |
| Francois Cedric | Chief Executive Officer | 0 | May 14, 2026 | 7 |
| Sullivan Timothy Eugene | Chief Financial Officer | 0 | May 14, 2026 | 7 |
| O'Brien Stephanie Monaghan | Director | 0 | May 14, 2026 | 3 |
| Dunlop A. Sinclair | Director | 0 | May 14, 2026 | 4 |
| Fonteyne Paul R. | Director | 0 | May 14, 2026 | 2 |
| Nicholson Nur | Chief Technical Officer | 0 | May 14, 2026 | 5 |
| Chopas James George | VP/Chief Accounting Officer | 0 | May 14, 2026 | 5 |
| DeLong Mark Jeffrey | Chief Business & Strat Officer | 0 | May 14, 2026 | 6 |
| Baumal Caroline | Chief Medical Officer | 0 | May 14, 2026 | 5 |
| Walbert Keli | Director | 0 | May 14, 2026 | 2 |
| Boucher Kelley | Chief People Officer | 0 | May 14, 2026 | 2 |
| Meltzer Leslie | Chief Research and Development | 0 | May 14, 2026 | 2 |
| Townsend Adam J. | Chief Commercial Officer | 84,050 | Jan 30, 2025 | 0 |
| Lewis Karen | Chief People Officer | 70,251 | Jan 30, 2025 | 0 |
| Eisele Jeffrey | Chief Development Officer | 55,312 | Jan 30, 2025 | 0 |
| Scheibler Lukas | Chief Research Officer | 68,299 | Dec 5, 2023 | 0 |
| Brown Victoria L. | Program Team Lead | 23,556 | Jan 24, 2023 | 0 |
| Grossi Federico | Chief Medical Officer | 94,884 | Jan 9, 2023 | 0 |
| Morningside Venture Investments Ltd | 10% Owner | 12,806,342 | Nov 18, 2021 | 0 |
| Perry Nicole D | Vice President - Accounting | 4,847 | Aug 3, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 18, 2025 (view filing) | Jul 16 | 2 days | Watson David O.General Counsel | SSale | −5.00K | $19.55 | −$97.8K | −3.7%128.7K after | 10b5-1 |
| Jul 18, 2025 (view filing) | Jul 17 | 1 day | Francois CedricChief Executive Officer | SSale | −19.7K | $20.21 | −$398.6K | −5.6%331.6K after | 10b5-1 |
| Aug 19, 2025 (view filing) | Aug 18 | 1 day | Watson David O.General Counsel | SSale | −5.00K | $27.80 | −$139.0K | −3.9%123.7K after | 10b5-1 |
| Aug 29, 2025 (view filing) | Aug 27-28 | 2 days | Francois CedricChief Executive Officer | SSale | −225.0K | $28.23 | −$6.35M | −42.2%307.9K after | 2 lots |
| Sep 3, 2025 (view filing) | Sep 2 | 1 day | Chopas James GeorgeVP/Chief Accounting Officer | SSale | −548 | $28.08 | −$15.4K | −1.0%53.7K after | |
| Sep 10, 2025 (view filing) | Sep 8 | 2 days | Sullivan Timothy EugeneChief Financial Officer | SSale | −32.7K | $27.86 | −$911.8K | −22.8%110.9K after | 10b5-1 |
| Sep 10, 2025 (view filing) | Sep 8 | 2 days | Sullivan Timothy EugeneChief Financial Officer | SSale | −10.0K | $27.83 | −$278.3K | −14.2%60.4K after | 10b5-1 |
| Sep 12, 2025 (view filing) | Sep 10 | 2 days | Watson David O.General Counsel | SSale | −20.0K | $26.17 | −$523.4K | −28.5%50.1K after | |
| Sep 17, 2025 (view filing) | Sep 15 | 2 days | Chopas James GeorgeVP/Chief Accounting Officer | SSale | −189 | $24.19 | −$4.57K | −0.4%53.5K after | |
| Sep 18, 2025 (view filing) | Sep 16 | 2 days | Watson David O.General Counsel | SSale | −5.00K | $24.34 | −$121.7K | −4.0%118.7K after | 10b5-1 |
| Sep 19, 2025 (view filing) | Sep 19 | Same day | Dunlop A. SinclairDirector | SSale | −31.1K | $22.95 | −$713.6K | −31.1%68.9K after | 10b5-1 |
| Oct 2, 2025 (view filing) | Sep 30 | 2 days | Dunlop A. SinclairDirector | SSale | −31.1K | $22.58 | −$702.1K | −47.8%34.0K after | 10b5-1 |
| Oct 15, 2025 (view filing) | Oct 10 | 5 days | Dunlop A. SinclairDirector | SSale | −31.1K | $23.72 | −$737.5K | −89.0%3.84K after | 10b5-1 |
| Oct 17, 2025 (view filing) | Oct 16 | 1 day | Watson David O.General Counsel | SSale | −5.00K | $25.22 | −$126.1K | −4.2%113.7K after | 10b5-1 |
| Oct 23, 2025 (view filing) | Oct 21 | 2 days | Sullivan Timothy EugeneChief Financial Officer | SSale | −10.0K | $28.03 | −$280.3K | −8.3%110.9K after | 10b5-1 |
| Nov 18, 2025 (view filing) | Nov 17 | 1 day | Watson David O.General Counsel | SSale | −5.00K | $20.06 | −$100.3K | −4.4%108.7K after | 10b5-1 |
| Dec 18, 2025 (view filing) | Dec 16 | 2 days | Watson David O.General Counsel | SSale | −5.00K | $24.49 | −$122.5K | −4.6%103.7K after | 10b5-1 |
| Jan 6, 2026 (view filing) | Jan 5 | 1 day | Baumal CarolineChief Medical Officer | SSale | −3.02K | $25.53 | −$77.1K | −3.2%91.2K after | |
| Jan 15, 2026 (view filing) | Jan 13 | 2 days | Watson David O.General Counsel | SSale | −5.78K | $22.19 | −$128.3K | −5.5%98.8K after | |
| Jan 15, 2026 (view filing) | Jan 13 | 2 days | Sullivan Timothy EugeneChief Financial Officer | SSale | −3.86K | $22.19 | −$85.6K | −3.5%107.1K after | |
| Jan 15, 2026 (view filing) | Jan 13 | 2 days | Nicholson NurChief Technical Officer | SSale | −2.62K | $22.19 | −$58.1K | −3.1%81.0K after | |
| Jan 15, 2026 (view filing) | Jan 13 | 2 days | Francois CedricChief Executive Officer | SSale | −10.2K | $22.19 | −$226.0K | −3.1%321.4K after | |
| Jan 15, 2026 (view filing) | Jan 13 | 2 days | Deschatelets PascalChief Scientific Officer | SSale | −2.28K | $22.19 | −$50.5K | −0.2%1.16M after | |
| Jan 15, 2026 (view filing) | Jan 13 | 2 days | DeLong Mark JeffreyChief Business & Strat Officer | SSale | −1.78K | $22.19 | −$39.5K | −2.1%83.1K after | |
| Jan 15, 2026 (view filing) | Jan 13 | 2 days | Chopas James GeorgeVP/Chief Accounting Officer | SSale | −873 | $22.19 | −$19.4K | −1.6%52.6K after | |
| Jan 21, 2026 (view filing) | Jan 20 | 1 day | Watson David O.General Counsel | SSale | −2.48K | $19.79 | −$49.0K | −2.5%96.4K after | |
| Jan 21, 2026 (view filing) | Jan 20 | 1 day | Sullivan Timothy EugeneChief Financial Officer | SSale | −2.89K | $19.79 | −$57.2K | −2.7%104.2K after | |
| Jan 21, 2026 (view filing) | Jan 20 | 1 day | Nicholson NurChief Technical Officer | SSale | −2.20K | $19.79 | −$43.6K | −2.7%78.8K after | |
| Jan 21, 2026 (view filing) | Jan 20 | 1 day | Francois CedricChief Executive Officer | SSale | −8.18K | $19.79 | −$161.9K | −2.5%313.2K after | |
| Jan 21, 2026 (view filing) | Jan 20 | 1 day | Deschatelets PascalChief Scientific Officer | SSale | −909 | $19.79 | −$18.0K | −0.1%1.16M after | |
| Jan 21, 2026 (view filing) | Jan 20 | 1 day | DeLong Mark JeffreyChief Business & Strat Officer | SSale | −1.33K | $19.79 | −$26.4K | −1.6%81.7K after | |
| Jan 21, 2026 (view filing) | Jan 20 | 1 day | Chopas James GeorgeVP/Chief Accounting Officer | SSale | −726 | $19.79 | −$14.4K | −1.4%51.9K after | |
| Jan 21, 2026 (view filing) | Jan 20 | 1 day | Baumal CarolineChief Medical Officer | SSale | −1.88K | $19.79 | −$37.2K | −2.1%89.3K after | |
| Jan 23, 2026 (view filing) | Jan 22 | 1 day | Watson David O.General Counsel | SSale | −7.83K | $21.77 | −$170.5K | −8.1%88.5K after | |
| Jan 23, 2026 (view filing) | Jan 22 | 1 day | Sullivan Timothy EugeneChief Financial Officer | SSale | −10.3K | $21.77 | −$223.9K | −9.9%93.9K after | |
| Jan 23, 2026 (view filing) | Jan 22 | 1 day | Nicholson NurChief Technical Officer | SSale | −7.72K | $21.77 | −$168.2K | −9.8%71.1K after | |
| Jan 23, 2026 (view filing) | Jan 22 | 1 day | Francois CedricChief Executive Officer | SSale | −27.2K | $21.77 | −$592.0K | −8.7%286.0K after | |
| Jan 23, 2026 (view filing) | Jan 22 | 1 day | Deschatelets PascalChief Scientific Officer | SSale | −5.93K | $21.77 | −$129.1K | −0.5%1.15M after | |
| Jan 23, 2026 (view filing) | Jan 22 | 1 day | DeLong Mark JeffreyChief Business & Strat Officer | SSale | −3.37K | $21.77 | −$73.4K | −4.1%78.4K after | |
| Jan 23, 2026 (view filing) | Jan 22 | 1 day | Chopas James GeorgeVP/Chief Accounting Officer | SSale | −2.06K | $21.77 | −$44.9K | −4.0%49.8K after | |
| Jan 23, 2026 (view filing) | Jan 22 | 1 day | Baumal CarolineChief Medical Officer | SSale | −2.80K | $21.77 | −$60.9K | −3.1%86.5K after | |
| Feb 13, 2026 (view filing) | Feb 11 | 2 days | DeLong Mark JeffreyChief Business & Strat Officer | SSale | −368 | $22.15 | −$8.15K | −0.3%114.6K after |